非小细胞肺癌(NSCLC)病人临床能应用的肿瘤标志物有限,且不能预测病变是否能行手术治疗,其敏感性和特异性也不高。关于肿瘤标志物对NSCLC病人治疗和随访期间的监测报道很少,大多数NSCLC病期已晚,其中只有少部分病人需要化疗,而恰当的化疗药也很有限。因此必须细致的评估治疗方案,以免对药物无反应的病变给以连续无效治疗,增加病人的 Clinically applicable tumor markers in non-small cell lung cancer (NSCLC) patients are limited, and cannot predict whether the lesion can be treated surgically, and its sensitivity and specificity are not high. There are few reports on the monitoring of tumor markers during the treatment and follow-up of NSCLC patients. Most NSCLC cases are late, of which only a small proportion of patients need chemotherapy, and the appropriate chemotherapy drugs are also limited. Therefore, it is necessary to carefully evaluate the treatment plan so as to avoid continuous invalid treatment of the disease that has no response to the drug and increase the patient’s